Compounding Pharmacy Issues Recall

News
Article

Innoveix Pharmaceuticals, Inc. is voluntarily recalling all sterile compounded drug products due to a lack of assurance of sterility.

Innoveix Pharmaceuticals, Inc. announced on October 10, 2019 that it is voluntarily recalling all sterile compounded drug products, within expiry, because of a lack of assurance of sterility.

Recalled products include injectable Human Chorionic Gonadotropin (HCG) and injectable Sermorelin w/GHRP2, which were distributed to customers and healthcare facilities. The recall was initiated after an FDA inspection was conducted at the facility.

While the company states the recall is out of “an abundance of caution” and it has not received any notice of adverse events, use of product that is intended to be sterile but is not sterile may result in serious and life-threatening infections. The company is advising customers to stop use of the products and to return any product they may have for a full refund. Adverse events may be reported to FDA through the agency’s MedWatch program.

Source: FDA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes